Im looking forward to see the gradual improvement in monthly (quarterly) production figures as revenues will lag it a bit.
getting to 100,000 chips per month is the first milestone i think which I assume will be achieved in this final quarter of the year.
also keen on seeing their plans to produce more virals and other accessories - this will likely start at very low numbers and ramp up gradualy, similar to what we saw with chips during this year.
finally, it will be great to hear about sectors and opportunities the company can now address beyond bio banking. Or maybe that is more likely to be discussed during the AGM.
with 50 parties in talks with BCT, this must include a varietty of exciting markets for growth we are not even aware of.
hope they use the quarterly to agaib reinforce the deal with Labcon as it got partially shadowed by the low cash balance, which is now no longer a hurdle with over $7m in the kitty .
exciting times ahead.
BCT Price at posting:
6.0¢ Sentiment: Buy Disclosure: Held